Brief Report: Long-Term Follow-Up of Adjuvant Pembrolizumab After Locally Ablative Therapy for Oligometastatic NSCLC.
- DOI
- 10.1016/j.jtocrr.2024.100667
- Published
- 2024 Jun
- Container
- JTO clinical and research reports
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jtocrr.2024.100667,
title = {Brief Report: Long-Term Follow-Up of Adjuvant Pembrolizumab After Locally Ablative Therapy for Oligometastatic NSCLC.},
author = {Cantor DJ and Davis C and Ciunci C and Aggarwal C and Evans T and Cohen RB and Bauml JM and Langer CJ},
year = {2024},
journal = {JTO clinical and research reports},
doi = {10.1016/j.jtocrr.2024.100667},
url = {https://doi.org/10.1016/j.jtocrr.2024.100667}
}RIS
TY - JOUR TI - Brief Report: Long-Term Follow-Up of Adjuvant Pembrolizumab After Locally Ablative Therapy for Oligometastatic NSCLC. AU - Cantor DJ AU - Davis C AU - Ciunci C AU - Aggarwal C AU - Evans T AU - Cohen RB AU - Bauml JM AU - Langer CJ PY - 2024 JO - JTO clinical and research reports DO - 10.1016/j.jtocrr.2024.100667 UR - https://doi.org/10.1016/j.jtocrr.2024.100667 ER -
APA
DJ, C., C, D., C, C., C, A., T, E., RB, C., JM, B., & CJ, L. (2024). Brief Report: Long-Term Follow-Up of Adjuvant Pembrolizumab After Locally Ablative Therapy for Oligometastatic NSCLC.. JTO clinical and research reports. https://doi.org/10.1016/j.jtocrr.2024.100667
Source records
- pubmed · retrieved 2026-09-25T11:29:15.982Z